Hyperfine Inc. ((HYPR)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hyperfine Inc.’s latest earnings call struck a cautiously upbeat tone, spotlighting a breakout fourth quarter, expanding margins and extended cash runway, even as management acknowledged modest full‑year growth and ongoing net losses. Executives framed 2025 as an inflection year where the business is shifting from development to commercial scale, but warned investors to expect some volatility as larger deals and international rollouts ramp.
Q4 Revenue Surge Marks Breakout Quarter
Hyperfine delivered Q4 revenue of $5.3 million, up 128% year over year from $2.3 million, driven by stronger system demand. Unit sales accelerated to 16 systems in the quarter versus 9 a year ago, helping second‑half 2025 revenue climb to $8.7 million compared with $4.8 million in the first half.
Gross Margins Push Above 50%
Profitability metrics improved sharply as Q4 gross profit reached $2.7 million, translating to a 50.9% gross margin and marking a second consecutive quarter above 50%. For the full year 2025, gross margin rose to 49.8%, an expansion of 410 basis points, while Q4 margins alone widened by 1,530 basis points versus the prior year.
Operating Discipline Lowers Cash Burn
Management highlighted tighter operating discipline, with research and development spending down 25% in Q4 and 22% for the full year. Net cash burn excluding financing fell to $5.7 million in Q4, a 30% year‑on‑year improvement, and declined 22% for 2025 to $29.9 million, easing pressure on the balance sheet.
Net Loss Narrows But Remains Significant
The company reduced its Q4 net loss to $5.9 million, or $0.06 per share, versus $10.4 million and $0.14 per share in the prior‑year period. For 2025, net loss improved to $35.6 million, or $0.43 per share, from $40.7 million in 2024, though results were affected by non‑cash warrant gains that partly mask the underlying operating shortfall.
Capital Raises Extend Cash Runway
Hyperfine moved to strengthen its capital position, raising more than $20 million of equity in October and drawing an initial $15 million tranche from a new debt facility that could total up to $40 million. Year‑end cash stood at $35.1 million, and management said the combined funding extends the company’s runway into 2028, assuming execution on future milestones.
Ambitious 2026 Outlook Targets Faster Growth
The company set aggressive 2026 targets, guiding revenue to $20–22 million for roughly 55% growth at the midpoint and gross margins in the 50–55% range. Total cash burn is expected to decline to $26–28 million in 2026, representing about a 10% reduction versus 2025 and including anticipated quarterly interest expense.
Clinical and Regulatory Wins Support Adoption
On the product front, Hyperfine secured FDA clearance in December for its Optive AI upgrade, the 11th software generation that improves diffusion‑weighted imaging. Supporting the device’s clinical credibility, the NEURO‑PMR study showed high concordance with conventional MRI, and the Yale PRIME study completed enrollment ahead of schedule.
Health Economics Bolster Commercial Story
The company underscored new health‑economic data from Jefferson Abington, where 143 scans indicated cost savings and a modeled one‑ to one‑and‑a‑half‑year payback for hospitals. Management said these findings are helping fuel commercial momentum with larger health systems and integrated delivery networks, and noted more than a dozen next‑generation systems sold since June.
International Expansion Plans Take Shape
Hyperfine is laying groundwork overseas with the Optive AI software now available in 10 European languages and regulatory clearance secured in India through a local partner. The firm plans to pursue approvals in Europe and the U.K. and expects a phased international rollout of its next‑generation scanner starting in the second half of 2026.
Full‑Year Revenue Lagged Momentum
Despite the strong finish, full‑year 2025 revenue rose just 5% to $13.6 million from $12.9 million, underscoring uneven performance earlier in the year. Management characterized 2025 as a tale of two halves, with growth heavily concentrated in the back half as commercial traction improved and larger deals began to contribute.
Ongoing Losses and Conditional Funding
The company remains meaningfully loss‑making, with a 2025 net loss of $35.6 million highlighting the scale‑up still required to reach break‑even. While cash levels are currently bolstered by recent equity and debt inflows, additional debt tranches under the new facility are contingent on achieving commercial milestones, tying capital access to execution.
Deal Complexity Adds Quarterly Volatility
Management cautioned that growing reliance on larger multi‑hospital and IDN contracts brings more complex procurement processes and budget reviews. That dynamic could drive quarter‑to‑quarter volatility in capital equipment revenue, making Hyperfine’s results more sensitive to customer budget cycles and internal approval timelines.
One‑Off Items Distort Near‑Term Comparisons
Q4 results were influenced by a system‑wide upgrade from an existing customer that management views as a likely one‑time event. Additionally, an accounting‑driven contract review temporarily reduced reported service revenue, complicating near‑term comparisons for investors tracking the recurring portion of the business.
Service Revenue and International Timing Headwinds
Service revenue appeared weaker in Q4 largely because of those accounting adjustments rather than underlying demand, according to management. International contributions are also expected to build gradually, as India placements ramp at a measured pace and the broader next‑generation scanner rollout abroad is not slated to begin until late 2026.
R&D Cuts Raise Innovation Trade‑Off Questions
While lower R&D spending is helping margins and cash burn, the 22% year‑over‑year reduction to $17.5 million sparked questions about long‑term innovation capacity. Executives positioned the cuts as part of a shift toward commercial scale, but acknowledged the need to balance cost control with targeted investment in future product development.
Guidance Signals Confidence in Scaling Momentum
Looking ahead, Hyperfine’s 2026 guidance assumes steadily stronger quarters as larger health system deals and an international launch of the next‑generation Swoop system kick in during the back half of the year. Management’s targets build on Q4’s momentum in revenue, margins and cash burn and reflect confidence that recently secured funding and clinical data can support the next stage of growth.
Hyperfine’s earnings call painted a picture of a company crossing an important commercial threshold, with a standout fourth quarter, better margins and a bolstered balance sheet. Investors, however, will be watching closely to see whether management can smooth out revenue lumpiness, sustain innovation under tighter R&D budgets and convert its promising pipeline of larger and international deals into durable, profitable growth.